CL115,347 (Cyanamid International) is a stable transdermally absorbed prostaglandin E2 analogue said to have an antiplatelet vasodilatory effect. In a trial of this drug in Raynaud's phenomenon 15 patients were given 1 mg CL115,347/day transdermally for 6 weeks and 14 were given a placebo. The treated group had fewer and shorter spasm attacks and better healing of ulcers as assessed on a visual analogue scale. Blood supply as measured by cold challenge plethysmography ('Medimatic SP2') was also improved by CL115,347, as were hand temperatures. The treated group also had a significant rise in platelet count, but initial decreases in platelet aggregation were not maintained up to the end of the study.
Belch, J. J. F., Shaw, B., Sturrock, R. D., Madhok, R., Leiberman, P., & Forbes, C. D. (1985). Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon. Lancet, 1(8439), 1180-1183. https://doi.org/10.1016/S0140-6736(85)92862-4